Effect of combined atorvastatin and ezetimibe compared to that of double-dose atorvastatin in very old patients with ACS
Abstract：Objective To compare the effect of different lipid-lowering therapies in very old patients with acute coronary syndrome (ACS).Methods One hundred and sixty-six ACS patients (86 males and 80 females) aged 80-88 (83.8±2.3) years admitted to our hospital from June 2012 to June 2014 were randomly divided into combined atorvastatin (10 mg/d) and ezetimibe (10 mg/d) treatment group (n=84) and double-dose atorvastatin (20 mg/d) treatment group (n=82).The patients were followed up for one year during which their primary end points were recorded.Results The serum hs-CRP level was significantly higher in combined atorvastatin and ezetimibe treatment group than in double-dose atorvastatin treatment group by the end of 3-month follow-up period (2.5±1.4 mg/L vs 2.1±1.5 mg/L,P=0.033).No significant difference was found in the incidence of major adverse cardiovascular events (MACE) between the two groups by the end of one year follow-up period (23.8％ vs 19.0％,P=0.473).No significant difference was found in MACE (cardiogenic death,non-lethal myocardial infarction,revascularization therapy),ischemic stroke,myalgia,myasthenia,etc (P ＜ 0.05).Cox regression analysis showed no significant difference in the risk of MACE between the two groups (HR=1.12,95 ％CI:0.51-2.55,P=0.743).Conclusion The long-term effect of combined atorvastatin and ezetimibe and double-dose atorvastatin is similar in very old ACS patients.
Keywords：acute coronary syndromeantilipemic agentsdrug therapycombinationC-reactive protein
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 5-8 )